

**APPENDIX A: Recommended timing of meningococcal vaccine doses,<sup>\*†</sup> within the routine schedule based on the outcome of shared clinical decision-making regarding meningococcal B vaccine<sup>1</sup>**

<b>Recommendations for MenB, based on shared clinical decision-making</b>			
<b>Recipient age group, years</b>	<b>Shared decision regarding MenB administration</b>		
	<b>No</b>	<b>Yes, at age 16 years</b>	<b>Yes, at age &gt;16 years</b>
<b>11–12</b>	MenACWY dose 1	MenACWY dose 1	MenACWY dose 1
<b>16</b>	MenACWY dose 2	MenACWY dose 2 + Bexsero <sup>#</sup> or MenACWY dose 2 + Trumenba <sup>◇</sup> or Penbraya followed by Trumenba 6 months later	MenACWY dose 2
<b>17–23</b>	N/A	NA	Bexsero <sup>#</sup> Or Trumenba <sup>◇</sup>

\*Assumes that a person has not previously been vaccinated with MenACWY or MenB.

†MenACWY vaccines are interchangeable; the same vaccine product is recommended but not required for all doses. Different manufacturers' MenB vaccines are not interchangeable.


#Two-dose series with doses administered  $\geq 1$  month apart.

◇Two-dose series with doses administered 6 months apart.

Adapted from:

- 1) Collins JP, Crowe SJ, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged  $\geq 10$  years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023. MMWR 2024;73:345–50. Available at <http://dx.doi.org/10.15585/mmwr.mm7315a4>.

**APPENDIX B: Recommended meningococcal vaccines for persons at increased risk for meningococcal disease due to serogroups A, B, C, W, or Y and who are due for both meningococcal A, C, W, and Y vaccine and meningococcal B vaccine<sup>1\*§¶#</sup>**



\* MenACWY products are interchangeable; the same vaccine product is recommended, but not required, for all doses. Different manufacturers' MenB vaccines are not interchangeable.

§ To determine whether MenACWY and MenB are indicated based on a person's risk factors and timing of any previous meningococcal vaccines, see <https://pubmed.ncbi.nlm.nih.gov/33417592/>

¶ If MenB was received previously but the vaccine manufacturer is not known, the series must be restarted with any licensed product to ensure completion of the series using products from a single manufacturer. See <https://pubmed.ncbi.nlm.nih.gov/33417592/>

# If Trumenba was received previously, Penbraya may be used provided the person has not received Penbraya previously or ≥6 months have passed since the previous dose of Penbraya.

Adapted from:

- 1) Collins JP, Crowe SJ, Ortega-Sanchez IR, et al. Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices – United States, 2023. MMWR Morb Moral Wkly Rep 2024;73:345-350. DOI: <http://dx.doi.org/10.15585/mmwr.mm7315a4>.